Combination drug for advanced lung cancer with MET protein
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two medicines for people with advanced non-small cell lung cancer that has a specific marker called MET overexpression. The trial hopes to see if adding the new drug (glumetinib) to standard chemotherapy works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of lung cancer that has spread and cannot be removed with surgery.
- Your tumor must test positive for a high level of MET protein (called MET overexpression).
- You must have already received both immunotherapy (like PD-1/PD-L1 drugs) and platinum-based chemotherapy.
- You cannot have had docetaxel or any previous MET-targeted drug.
- You must be in relatively good health (able to care for yourself and get around).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a new combination of two targeted drugs, glumetinib and osimertinib, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can help control the cancer better than standard treatments.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
Hear when a new Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.